About: Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Sector: Healthcare
Industry: Biotechnology
Latest price: $71.91 (-2.02%)
MNPR NASDAQ Monopar Therapeutics Inc
Monopar Therapeutics Inc share price
Atividade de preço de MNPR
Último preço
$ 71,910
Variação (24h)
-1,48 USD (2,02%)
Volume
163.10K
Volume (média 4 sem.)
-
Abertura
$ 73,90
Variação do dia
$ 70,65 - $ 75,29
Fechamento anterior
$ 73,39
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
MNPR price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals